Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

3218 - Patient preference of trastuzumab administration (SC versus IV) in HER2-positive metastatic breast cancer: Results of the randomised Metaspher study


10 Oct 2016


Poster display


Xavier Pivot


Annals of Oncology (2016) 27 (6): 68-99. 10.1093/annonc/mdw365


X. Pivot1, J. Spano2, E. Marc3, P. Cottu4, C. Jouannaud5, V. Pottier6, L. Moreau7, J. Extra8, A. Lortholary9, P. Rivera10, D. Spaeth11, H. Attar-Rabia12, C. Benkamoun12, L. Dima-Martinez12, N. Esposito13, J. Gligorov14

Author affiliations

  • 1 Oncology, CHU Besançon, Hôpital Jean Minjoz, 25000 - Besançon/FR
  • 2 Medical Oncology, Pitié-Salpêtrière Hospital, 75013 - Paris/FR
  • 3 Oncology, Hôpital St. Louis, Paris/FR
  • 4 Medical Oncology, Institut Curie, 75248 - Paris/FR
  • 5 Oncology, Institut Jean Godinot, Reims/FR
  • 6 Oncology, Centre Léonard de Vinci, Dechy/FR
  • 7 Oncology, Pole Sante Republique, Clermont-Ferrand/FR
  • 8 Oncologie Médicale, Institute Paoli Calmettes, 13274 - Marseille/FR
  • 9 Oncology, Centre Catherine de Sienne, Nantes/FR
  • 10 Oncology, Centre Claudius-Regaud, Toulouse/FR
  • 11 Oncology, Centre d’Oncologie de Gentilly, 54000 - Nancy/FR
  • 12 Clinical Research, laboratoire Roche, Boulogne-Billancourt/FR
  • 13 Statistical Research Department, laboratoire Roche, Boulogne-Billancourt/FR
  • 14 Medical Oncology Department, Assistance Publique Hôpitaux de Paris – Tenon, Paris/FR


Abstract 3218


HANNAH (NCT00950300) and PREFHER (NCT01401166) international, randomised studies validated the subcutaneous (SC) formulation of trastuzumab as effective and safe as intravenous (IV) and highly preferred by patients in early breast cancer. The present randomized Metaspher trial (NCT 01810393) assessed patient's preference in metastatic setting.


Patients with HER2-positive metastatic breast cancer who completed a first line chemotherapy with trastuzumab (IV) and achieved a long term response lasting more than 3 years were randomised to receive 3 cycles of 600 mg fixed-dose adjuvant trastuzumab SC, followed by 3 cycles of standard IV, or the reverse sequence. Primary endpoint was overall preference for SC or IV at cycle 6, assessed by Patient Preference Questionnaire (PPQ). Secondary endpoints included healthcare professional (HCP) satisfaction, assessed by questionnaire; safety and tolerability, assessed by NCI-CTCAE v4.0; quality of life assessed by QLQ C30 questionnaire. The modified-Intent-To-Treat population (m-ITT) included patients who received both routes of administration and who completed the last question of PPQ. The safety population included all enrolled patients who received at least one dose of treatment.


113 patients were randomised. SC was preferred by 79/92 evaluable m-ITT patients (85.9%, 95% CI [78.8;93.0]; p 


Patients preferred trastuzumab SC. The safety profile was consistent with the known IV profile with no safety concerns raised. Next step will assess the follow up of this cohort of long responder patient with metastatic breast cancer.

Clinical trial identification

NCT 01810393

Legal entity responsible for the study





X. Pivot: consultant for Roche Amgen Novartis Pierre Fabre Eisai. J-P. Spano: Consultant for Roche.

E. Marc, D. Spaeth: Roche. H. Attar-Rabia, C. Benkamoun, L. Dima-Martinez, N. Esposito: Employed by Roche. J. Gligorov: Consultant for Roche, Novartis, Eisai, Pfizer, Genomic Health. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings